More on KOD
Data
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $32.87 |
|
|||
| Open | $32.87 | ||||
| 52 Wk High | $ | ||||
| 52 Wk Low | $ | ||||
| Day High | $32.87 | ||||
| Day Low | $32.87 | ||||
| P/E | N/A | ||||
| EPS | $ | ||||
| Volume | 272 | ||||
- H.C. Wainwright Reiterates Buy Rating on Kodiak Sciences Inc. (KOD)
- Form SCHEDULE 13G Kodiak Sciences Inc. Filed by: PRICE T ROWE ASSOCIATES INC /MD/
- Kodiak Sciences Inc. (KOD) Misses Q2 EPS by 7c
- Form 10-Q Kodiak Sciences Inc. For: Jun 30
- Form 8-K Kodiak Sciences Inc. For: Aug 13
- Kodiak Sciences Announces Recent Business Highlights and Second Quarter 2026 Financial Results
- Kodiak Sciences enrolls first patients in Phase 3 DME trial
- Kodiak Sciences Announces First Patients Enrolled in Global Phase 3 ALTO trial of KSI-501 in Patients with Diabetic Macular Edema
- Kodiak Sciences completes enrollment in Phase 3 PEAK trial cohort
- Kodiak Sciences Completes Enrollment in First Pivotal Cohort in the Phase 3 PEAK Trial of KSI-101 for Macular Edema Secondary to Inflammation and Reaffirms Topline Clinical Data Release Remains on Tra
Entities mentioned with KOD
- Earnings | View Related Stories »
- FDA | View Related Stories »
- JPMorgan | View Related Stories »
- 13G | View Related Stories »
- Jefferies & Co | View Related Stories »
- Maynard Um | View Related Stories »
- Mark Zuckerberg | View Related Stories »
- ARK | View Related Stories »
- Show More...
